IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. has experienced significant stock performance in the past six months, with the share price increasing by 41.20%. The year-to-date total return for IDXX stock is 55%. In Q1 2025, shares rose 9% after the company's earnings release, with EPS topping analyst estimates and raised fiscal 2025 guidance. In Q2 2025, IDEXX reported strong results, with revenue increasing 11% and EPS surpassing forecasts, leading to a significant uplift in its full-year guidance for 2025, and the stock surged 27.5%. In Q3 2024, IDEXX reported 6% organic revenue growth, with CAG Diagnostics recurring revenue increasing 7% organically and the Water business demonstrating 13% organic growth.

IDEXX Laboratories' business model is largely driven by recurring revenue streams, contributing to stable demand for its products and services. A significant portion of its revenue comes from consumables, software subscriptions, and reference laboratory services. Customer contractual arrangements often involve multi-year commitments, further contributing to consistent demand. The company's continuous investment in research and development also helps to refresh product life cycles. The recurring nature of its revenue and customer commitments suggest a generally stable demand profile rather than pronounced seasonality.

IDEXX Laboratories, Inc. specializes in developing, manufacturing, and distributing products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. The company operates in the Healthcare sector, specifically in the Biotechnology: In Vitro & In Vivo Diagnostic Substances and Medical Supplies industries. The company's major products and services are categorized into three primary segments: Companion Animal Group (CAG), Water Quality Products, and Livestock, Poultry, and Dairy (LPD). The CAG segment provides diagnostic products and services for veterinarians, including in-clinic diagnostic instruments, rapid assay tests, and a global network of reference laboratories. The Water Quality Products segment offers solutions for measuring microbiological parameters in water. The LPD division provides diagnostic tests and services to manage the health status of livestock and poultry.

IDEXX Laboratories operates globally, serving customers in over 175 countries. Its corporate headquarters are in Westbrook, Maine, USA, and its European headquarters are in Hoofddorp, Netherlands. The company's infrastructure includes a network of more than 80 reference laboratories, advanced manufacturing sites, and strategically located sales and distribution offices.

IDEXX Laboratories is recognized as a global leader in veterinary diagnostics and pet healthcare innovation. The company is committed to advancing animal health and well-being, providing tools, technology, and insights to veterinarians to enhance medical care and practice efficiency. There have been no specific public events that have negatively impacted IDEXX Laboratories' brand reputation in the past year. However, the company acknowledges potential technological risks related to AI integration and operational risks such as cybersecurity breaches.

The ownership structure of IDEXX Laboratories stock includes institutional, retail, and individual investors. Approximately 87.84% of the stock is owned by institutional investors, with Vanguard Group Inc. owning the most shares. Individual investors and public companies own approximately 41.40% of the stock, while insiders hold about 0.28%.